Monitor for follow-up transactions from other insiders; while this is a modest sale, the timing relative to earnings or clinical developments could signal sentiment. The derivative exercises suggest option expiration or vesting, not necessarily bearish intent.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $9.30entry
- T+1 · 8mo ago −0.97%α −1.24% · $9.21
- T+5 · 8mo ago +5.38%α +7.42% · $9.80
- T+20 · 7mo ago +3.98%α +0.20% · $9.67
- T+60 · 5mo ago −9.35%α −19.84% · $8.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Theresa Heggie sold 49,933 shares of BioCryst Pharmaceuticals for $504,823 in an open-market transaction. This sale was accompanied by the exercise of derivative securities related to the same share amount, including a non-cash exercise. The total open-market sale represents a modest but notable insider disposition.
Key Financial Metrics
Key Facts
- Director Theresa Heggie sold 49,933 shares at $10.11 per share for total proceeds of $504,823.
- On the same day, she exercised derivative securities for 99,866 shares (two separate exercises: one at $6.30 and one at $0 strike price).
- Only the open-market sale (Form 4 code 'S') represents a cash transaction; the derivative exercises (code 'M') are non-cash events and do not reflect new investment or direct selling pressure.
- Total open-market selling in the past 7 days: $504,823 (one insider). Recent 30-day selling totals $1.9M across two insiders.
Financial Impact
$504,823 in open-market sales by a director
Risk Factors
- Perception of insider selling may weigh on sentiment if not contextualized.
- Further sales from other insiders could indicate broader concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-BCRX-1774382654020 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers